Hépato-Gastro & Oncologie Digestive


Prise en charge de la neutropénie fébrile en cancérologie Volume 26, supplément 1, Octobre 2019

  • [1] de Naurois J., Novitzky-Basso I., Gill M.J., Marti F.M., Cullen M.H., Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21:v252-v256. ESMO Guidelines Working GroupSuppl. 5
  • [2] Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol 2018 ; 36 (14) : 1443-1453.
  • [3] Klastersky J, de Naurois J, Rolston K, et al. ; ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 2016 ; 27 (Suppl. 5) : v111-v118.
  • [4] Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258-2266. 10
  • [5] Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol 2015 ; 33 (5) : 465-71.
  • [6] André S., Taboulet P., Elie C. Febrile neutropenia in French emergency departments: Results of a prospective multicentre survey. Crit Care. 2010;14:R68. 2
  • [7] Legrand M., Max A., Peigne V. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2012;40:43-49. 1
  • [8] Freifeld A.G., Bow E.J., Sepkowitz K.A. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:e56-93. Infectious Diseases Society of America4
  • [9] Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004 ; (39 Suppl. 1) : S25-31.
  • [10] Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother 2014 ; 58 (7) : 3799-803.
  • [11] Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000 ; 18 (16) : 3038-51.
  • [12] Carmona-Bayonas A, Gómez J, González-Billalabeitia E, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer 2011 ; 105 (5) : 612-7.
  • [13] Averbuch D, Orasch C, Cordonnier C, et al. ; ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013 ; 98 (12) : 1826-35.
  • [14] Kern W.V., Marchetti O., Drgona L. Oral antibiotics for fever in low-risk neutropenic patients with cancer : a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. J Clin Oncol. 2013;31:1149-1156. 9
  • [15] Beyar-Katz O, Dickstein Y, Borok S, Vidal L, Leibovici L, Paul M. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev 2017 ; 6 : CD003914.
  • [16] Luther M.K., Timbrook T.T., Caffrey A.R., Dosa D., Lodise T.P., LaPlante K.L. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: A systematic review and meta-analysis. Crit Care Med. 2018;46:12-20. 1
  • [17] Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev 2013 ; (6) : CD003038.
  • [18] Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): An open-label, randomised, controlled phase 4 trial. Lancet Haematol 2017 ; 4 (12) : e573-e583.